Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inmune Bio ( (INMB) ) just unveiled an update.
INmune Bio Inc. announced the termination of its Amended and Restated At-The-Market Sales Agreement with RBC Capital Markets, LLC and BTIG, LLC, effective December 19, 2025. The company had previously raised approximately $10.5 million through the sale of 1,353,469 shares of common stock under this agreement, and the termination incurs no penalties or additional expenses.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
Average Trading Volume: 460,391
Technical Sentiment Signal: Sell
Current Market Cap: $54.23M
For an in-depth examination of INMB stock, go to TipRanks’ Overview page.